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ABSTRACT 1	  
PURPOSE: Antibiotic lock solutions (ALS) are used for management of catheter-related 2	  
bloodstream infections. We compared activity of vancomycin and telavancin against 3	  
biofilm-forming Staphylococcus epidermidis, Enterococcus faecalis, and 4	  
Staphylococcus aureus. 5	  
METHODS: An established in vitro central venous catheter antibiotic lock model was 6	  
used to evaluate: vancomycin (5 mg/mL) and telavancin (5 mg/mL), with and without 7	  
preservative-containing heparin sodium (benzyl alcohol 0.45%) 2500 units/mL; and 8	  
heparin and normal saline.  ALS were introduced after 24h bacterial growth in catheters 9	  
incubated at 35°C.  After 72h exposure to lock solution, catheters were drained, flushed, 10	  
and cut into segments for CFU/mL quantification. 11	  
RESULTS: Against S. epidermidis, vancomycin and telavancin (with and without 12	  
heparin) demonstrated similar activity.  Against E. faecalis, vancomycin alone (no 13	  
heparin) was more active than telavancin alone (p<0.01).  Against S. aureus, 14	  
vancomycin plus heparin demonstrated activity similar to vancomycin alone. Both 15	  
demonstrated  greater activity than telavancin (p<0.02). When heparin was added to the 16	  
vancomycin lock, activity against S. epidermidis and E. faecalis was reduced (p<0.01). 17	  
Telavancin activity was not significantly changed with addition of heparin. 18	  
CONCLUSION: Both telavancin and vancomycin significantly reduced biofilm burden 19	  
against biofilm-forming S. epidermidis, E. faecalis, and S. aureus, but were unable to 20	  
completely eradicate these bacteria in the in vitro catheter model. 21	  
3	  
	  
INTRODUCTION 22	  
Staphylococcal and enterococcal infections are a major problem in hospital 23	  
settings, especially among patients with indwelling devices.1  These infections are often 24	  
caused by biofilm-producing strains which are difficult to eradicate and which may 25	  
progress to bacteremia.  Vancomycin therapy is one of the recommendations in the 26	  
Infectious Diseases Society of America catheter-related infection management 27	  
guidelines when systemic antibiotics are used in combination with antibiotic lock 28	  
solutions (ALS) to treat catheter-related bacteremia while attempting to retain the 29	  
catheter.2   30	  
 Telavancin is a lipoglycopeptide antibiotic with a core chemical structure similar 31	  
to the glycopeptide vancomycin.  Unlike vancomycin, telavancin possesses a second 32	  
mechanism of action that causes a rapid depolarization and loss of the functional 33	  
integrity of the bacterial membrane.3, 4  Clinical data support the use of telavancin in the 34	  
treatment of complicated skin and soft-tissue infections and nosocomial pneumonia 5-8, 35	  
while animal model data suggest efficacy in the treatment of bacteremia, endocarditis, 36	  
osteomyelitis, and meningitis caused by gram-positive pathogens.9-13 Of great interest is 37	  
the activity of telavancin against biofilm-producing staphylococci and enterococci.6, 14 38	  
We previously described the activity of daptomycin and vancomycin on formed biofilms 39	  
in an in vitro central venous catheter model.15  40	  
We have used a validated catheter modeling system to assess the activity of 41	  
telavancin or vancomycin alone or in combination with the anticoagulant heparin 42	  
(containing benzyl alcohol preservative) in the eradication of biofilm-forming 43	  
staphylococci and enterococci. This model uses 72 hour lock times that are useful in 44	  
clinical settings, particularly in the management of hemodialysis catheter infections.16, 17    45	  
4	  
	  
MATERIALS AND METHODS: 46	  
Bacterial strains.  Known biofilm-producing strains of Staphylococcus epidermidis 47	  
(ATCC 35984), methicillin-susceptible Staphylococcus aureus (MSSA, ATCC 35556), 48	  
and Enterococcus faecalis (ATCC 29212; vancomycin- susceptible) were evaluated.  In 49	  
addition, biofilm-forming clinical isolates of S. epidermidis (L369D, from urine), 50	  
vancomycin-resistant E. faecalis (VRE, L2022, from tissue), methicillin-resistant S. 51	  
aureus (MRSA; L32 and L83, from blood), and MSSA (L2, from blood), were evaluated. 52	  
The biofilm forming ability of each strain, as determined by optical density 53	  
measurements, has been  previously described.14  Minimum inhibitory concentrations of 54	  
vancomycin (1 to 2mg/L except the VRE strain at 256mg/L) and telavancin (0.03-0.25 55	  
mg/L) were also previously tested. 14 56	  
Lock solutions. Vancomycin hydrochloridea (5mg/mL final concentration) and 57	  
telavancinb (5mg/mL final concentration) were obtained from commercial pharmacy 58	  
stock. Telavancin drug product (telavancin for injection, 250mg vial) also contains 59	  
mannitol (312.5mg) and hydroxypropylbetadex (2500mg) to increase solubility.  Stock 60	  
solutions of each antibiotic were freshly prepared each day. Heparin sodium solution 61	  
(5000units/mL with 0.9% benzyl alcohol; Hospira, Lake Forest, IL) was obtained from 62	  
commercial pharmacy stock and diluted with normal saline (NS; without preservatives) 63	  
or antibiotic solution to a final concentration of 2500units/mL which contained 0.45% 64	  
benzyl alcohol. These lock solutions have demonstrated compatibility and stability up to 65	  
72h at 37°C.18 66	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a	  Hospira,	  Lake	  Forest	  IL,	  lot	  #	  943903A,	  12070DD	  
b	  Astellas	  Pharma,	  Deerfield	  IL,	  lot#	  2029222	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Medium. Supplemented Tryptic soy broth (STSB, Difco, Becton Dickinson Co., Sparks, 67	  
MD) with 1% dextrose, 2% sodium chloride, 25 mg/L calcium chloride, and 12.5 mg/L 68	  
magnesium was used for all catheter models.15, 19 Colony counts were determined using 69	  
tryptic soy agar (TSA, Difco, Becton Dickinson Co., Sparks, MD). 70	  
Device inoculation and treatment.  Two sets of catheters were processed. For all 71	  
catheters, a 0.5 McFarland standard of each test organism (noted above) was diluted in 72	  
STSB and added to the lumen of triple-lumen polyurethane central venous catheters 73	  
(Arrow-Howes CVC® 15703, Reading, PA).15, 19  Starting inocula were ~106 CFU/mL, 74	  
verified by colony count on TSA.  After 24h biofilm development at 35°C, one set of 75	  
catheters was processed for CFU/mL to determine a baseline of biofilm formation. The 76	  
other catheters were drained and lock solution instilled. Under sterile conditions, each 77	  
drug was injected into each access port sufficient to fill the catheter lumen.  Catheters 78	  
were then clamped at the distal end.  This procedure was also repeated with separate 79	  
CVC containing anticoagulant (preservative-containing heparin sodium) or NS.  Each 80	  
catheter was then incubated at 35°C for an additional 72h.  Each organism was tested 81	  
against each agent at least in triplicate.  82	  
Recovery of treated organisms.  Catheter fluid was removed and discarded following 83	  
incubation.   A sterile needle was introduced into the open lumen and 1 mL of sterile NS 84	  
was flushed through each lumen and collected.  To optimize yield of viable bacteria, the 85	  
flushed saline was sonicated at 60Hz for 1 minute, then vortexed for 15 seconds as 86	  
previously described.15  Additionally, 3 cm cut pieces of each catheter were sonicated 87	  
and vortexed in 3 mL of sterile NS. Sonication served to separate clusters of cells for 88	  
quantification, as well as removing biofilm from the catheter surface. Serial dilutions of 89	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the flushed saline and saline used to sonicate and vortex the cut segments were plated 90	  
on TSA for colony count enumeration.  The limit of detection for the flushed, sonicated, 91	  
and vortexed cultures from the lumen and the sonicated and vortexed saline of the 92	  
catheter segment is 2.0 log10 CFU/mL.15   93	  
Drug Stability. Concentrations of vancomycin and telavancin with and without heparin 94	  
were evaluated before and after 72h incubation in CVC at 35°C. Vancomycin 95	  
concentrations were determined by a homogeneous particle-enhanced turbidmetric 96	  
immunoassay (PETIA; Architect, Multigent®; Abbott Diagnostics Abbott Park, IL, USA) 97	  
at the Providence Veteran Affairs Medical Center.20  The vancomycin assay has a 98	  
detection range of 0.5 to 80.0 µg/mL, and an intra- and inter-day CV% of <2.0% and 99	  
<5.0%, respectively. Telavancin concentrations were determined by Theravance, Inc. 100	  
using liquid chromatography mass spectrometry.21, 22   101	  
Data analysis.  Each catheter was used to test one lock bacterial strain combination in 102	  
triplicate. The log10 CFU/mL from the flushed saline and saline used to sonicate and 103	  
vortex the cut catheter segment were added together to give a total log10 CFU/mL 104	  
result. This allowed for quantification of the total biofilm remaining in the catheter and 105	  
allowed for combining catheter lumens of different gauges. These triplicate total results 106	  
were subtracted from the baseline catheter (0h lock solution, ~108 CFU/mL, also in 107	  
triplicate) for each strain (n=9 per strain), to determine antimicrobial activity (reduction in 108	  
log10CFU/mL, or kill). Average activity and standard error of the mean were calculated 109	  
for each species and lock solution. Activity was compared between groups using one-110	  
way ANOVA followed by Tukey’s post-hoc test for multiple comparisons.  All statistical 111	  
7	  
	  
analyses were performed using SPSS statistical software (release 20; SPSS, Inc. 112	  
Chicago, IL.). A p value of < 0.05 indicates statistical significance.  113	  
8	  
	  
RESULTS 114	  
Antimicrobial activity in a catheter model.  Activity of tested lock solutions are shown 115	  
in Figure 1a-c.  The activity of each lock solution was averaged for S. epidermidis, E. 116	  
faecalis, and S. aureus, as the results were similar for each species. The catheters 117	  
processed after 24h incubation with media and bacteria, with no lock solution, yielded 118	  
107-108 CFU/mL for each strain. This served as the baseline biofilm formation for 119	  
calculating activity of the lock solutions. Against S. epidermidis, all antibiotic lock 120	  
solutions were more active than normal saline (p<0.01). Telavancin plus heparin 121	  
demonstrated the most activity, but was not significantly more active than telavancin 122	  
alone or vancomycin alone.  The addition of heparin to vancomycin, however, reduced 123	  
activity compared to vancomycin alone (mean difference 0.79, 95%CI 0.15-1.42, 124	  
p<0.01).  125	  
Against E. faecalis, telavancin demonstrated minimal activity. Vancomycin alone 126	  
was more active than the other lock solutions (p<0.01). Vancomycin activity was 127	  
reduced by the addition of heparin (mean difference 2.89, 95%CI 2.42-3.36, p<0.01). 128	  
Normal saline was more active than any heparin-containing lock solution or telavancin 129	  
alone (p<0.01), suggesting that heparin reduces antimicrobial activity of the lock 130	  
solution.  131	  
 Against S. aureus, antibiotic lock solutions demonstrated more activity than 132	  
heparin alone (p<0.02), however telavancin and telavancin plus heparin were not 133	  
significantly more active than normal saline.  Vancomycin plus heparin demonstrated 134	  
the most activity, but not significantly different from vancomycin alone.  The addition of 135	  
9	  
	  
heparin to the antibiotic lock solution did not have a significant effect on the activity of 136	  
either antibiotic against these strains. 137	  
  138	  
Drug stability.  Telavancin and vancomycin solutions were evaluated for concentration 139	  
at least in duplicate before and after incubation.  Lock solutions increased in 140	  
concentration after 72h incubation (Table 1).  We attempted measuring concentrations 141	  
of heparin-containing lock solutions after 72h incubation, however, the added heparin 142	  
interfered with interpretation of these results. (data not shown).  143	  
10	  
	  
DISCUSSION 144	  
As large numbers of patients continue to be dialyzed through long-term intravascular 145	  
catheters and long-term intravascular catheter use continues to be important in caring 146	  
for many patients; a niche exists for the ideal antimicrobial agent to be used as an ALS 147	  
for catheter salvage.  If successful, ALS use should reduce the cost and complications 148	  
of catheter removal and reinsertion.  149	  
In a previous study, telavancin prevented biofilm formation by biofilm-forming 150	  
staphylococci and enterococci at concentrations below the MIC.14 In the current study 151	  
testing eradication of formed biofilms, telavancin at concentrations 20,000-166,666x the 152	  
MIC and vancomycin at concentrations 2,500-5,000x the MIC (except for the VRE strain 153	  
which was ~20x the MIC) reduced the bacterial burden, but did not completely eradicate 154	  
these strains. While the concentrations of both vancomycin and telavancin increased 155	  
over the 72h period, we believe this was due to losses in volume from the lumen during 156	  
incubation.  157	  
The activity of vancomycin against vancomycin-resistant enterococci (VRE) may reflect 158	  
the high concentration used (~20x the MIC). Of note, the VRE strain produced less 159	  
biofilm than the other strains, making it less difficult to eradicate. We hypothesize that 160	  
the decreased activity of telavancin against S. aureus and E. faecalis may be partially 161	  
due to the presence of mannitol (125% w/w telavancin) in the drug formulation.23  162	  
Mannitol is a sugar alcohol that can be fermented by S. aureus and some Enterococcus 163	  
strains, but not by S. epidermidis. Mannitol increases  S. aureus biofilm formation,24 164	  
11	  
	  
which may lead to reduced ALS activity. The activity of the ALS tested against these 165	  
strains may be isolate-specific, likely reflecting the amount of biofilm produced.  166	  
Activity of the telavancin lock solutions may have been reduced by drug binding to the 167	  
catheter surface.  Recent recommendations have suggested adding polysorbate 80 (P-168	  
80) and dimethyl sulfoxide (DMSO) to telavancin for MIC testing to decrease binding to 169	  
the polystyrene surface resulting in a decreased MIC.25  MICs were previously tested 170	  
without P-80 and DMSO and may appear falsely elevated compared to MICs with the 171	  
more recent method.  Addition of P-80 and DMSO may increase activity of lock 172	  
solutions by decreasing binding to the polyurethane catheter; however, clinical utility is 173	  
limited unless a commercial product containing these additives is available.   174	  
Addition of benzyl alcohol-containing heparin to the antibiotic solution significantly 175	  
reduced antimicrobial activity of vancomycin against S. epidermidis and E. faecalis, 176	  
which we hypothesize may be due to stimulated biofilm growth. The influence of heparin 177	  
and benzyl alcohol on staphylococcal biofilm growth has been reported.26-29  Data on 178	  
the influence of heparin and benzyl alcohol on enterococcal biofilms are lacking.  The 179	  
minimal activity for all locks containing heparin may demonstrate heparin-induced 180	  
biofilm growth in enterococci. We did not observe a reduction in antibiotic activity with 181	  
heparin against S. aureus, which may be concentration-dependent. A previous study by 182	  
our laboratory demonstrated significant reductions in activity of vancomycin 2mg/mL, 183	  
linezolid 1mg/mL and 2mg/mL in combination with heparin 5000 units/mL (benzyl 184	  
alcohol 0.45%). (unpublished data) 185	  
12	  
	  
Normal saline demonstrated greater activity in our in vitro assay than expected. This is 186	  
likely due to disturbance of biofilm and removal of planktonic bacteria during lock 187	  
solution instillation and removal, which was not quantified.  Normal saline has previously 188	  
demonstrated a reduction in formed biofilms of ~1log10 CFU/mL over 24h.30 Detachment 189	  
of some planktonic bacteria from the biofilm would be expected due to the lack of 190	  
nutrients in the lock solutions and a 72h incubation period. High antibiotic 191	  
concentrations or osmotic stress present in the ALS can stimulate biofilm formation,31 192	  
but as these are absent in saline solutions, detachment may be greater. Planktonic 193	  
bacteria that detached from the biofilm would either be removed during lock solution 194	  
withdrawal or potentially killed in an ALS; however these bacteria were not quantified in 195	  
our study. This exemplifies the clinical importance of lock withdrawal instead of flushing 196	  
lock solutions (and any planktonic bacteria within them) into the patient.   197	  
We hypothesize that the activity of normal saline is related to the amount of biofilm 198	  
produced by each strain tested, as demonstrated by saline having particularly more 199	  
activity than expected against the VRE strain that produced less biofilm. It is also 200	  
important to note, that activity of the solutions average ~2-3 log10 CFU/mL, even for the 201	  
antibiotic-containing lock solutions. This reduction from a baseline biofilm of 108 202	  
CFU/mL, left ~105-106 CFU/mL remaining in the catheter lumen.  Activity may be 203	  
increased by repeated lock instillation and removal, as in clinical practice. 204	  
There are some limitations to this work. A small number of isolates were tested. There 205	  
are multiple possible explanations for the inability of the ALS tested to eradicate the 206	  
microbial load which was not explored further, such as additives inhibiting bactericidal 207	  
activity of antibiotics tested or stimulating  biofilm formation.  Increased biofilm formation 208	  
13	  
	  
could also be interpreted as larger biomass growth, and/or stronger attachment, both of 209	  
which would result in more recovered cells at 72h.   210	  
 211	  
  212	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CONCLUSIONS 213	  
Telavancin and vancomycin are active in reducing biofilm-forming staphylococci and 214	  
enterococci in a central venous catheter model, but were unable to completely eradicate 215	  
the biofilm-forming strains evaluated.  Addition of preservative-containing heparin 216	  
sodium 2500 units/mL to vancomycin reduces activity against S. epidermidis and E. 217	  
faecalis.  Finding the ideal ALS with antibiofilm activity and a minimal side-effect profile 218	  
remains of great interest to investigators and to the clinical community. 219	  
  220	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Figure 1. Log reduction (CFU/mL; mean ± standard error of the mean) of an inoculated 
catheter containing biofilm-forming A) Staphylococcus epidermidis, B) Enterococcus 
faecalis, and C) Staphylococcus aureus locked for 72h with antibiotic, heparin, or normal 
saline.c  
 
A S. epidermidis (2 strains: ATCC35984 and clinical strain L369D; n=18) 
B E. faecalis (2 strains: ATCC29212 and clinical strain L2022; n=18) 
C S. aureus (4 strains: 2 MSSA: ATCC35556 and clinical strain L2, and 2 MRSA: 
clinical strains L32 and L83; n=36) 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
c	  NS= normal saline 
Hep = heparin sodium 2500units/mL with 0.45% benzyl alcohol  
TLV = telavancin 5mg/mL 
TLVH= telavancin 5mg/mL with heparin 
VAN = vancomycin 5mg/mL 
VANH= vancomycin 5mg/mL with heparin 
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Table 1.  Concentrations of antibiotic lock solution stock and after 72 hour incubation in 
a central venous catheter.  Targeted concentrations were 5 mg/mL. 
 
 
Antibiotic 
Stock Concentration 
(mg/mL) 
72 hour Incubation 
(mg/mL) 
Telavancin 4.5 ± 0.8 4.9 ± 0.1 
Vancomycin 5.0 ± 0.2 5.8 ± 0.02 
 
